Monthly Archives: May 2015

AUDIOEYE, INC. LAWSUIT (AEYE)

Class Action Lawsuit Against Audioeye, Inc. on Behalf of Audioeye, Inc. Investors

Audioeye, Inc. Lawsuit Details
On April 21, 2015 a federal securities class action law suit was filed on behalf of investors in AudioEye, Inc. (NASDAQ: AEYE)) common stock. The complaint alleges that AudioEye made false and/or misleading statements and/or failed to disclose that, among other matters, the Company’s financials contained errors regarding classification of revenue. On April 1, 2015, AudioEye announced that its financial statements issued for the quarters ended March 31, June 30 and September 30, 2014 will be restated due to errors. AudioEye also stated that its preliminary earnings release issued by the Company on January 12, 2015 relating to the quarter and year ended December 31, 2014 should no longer be relied upon.

AUDIOEYE, INC. LAWSUIT

AUDIOEYE, INC. LAWSUIT

Legal Help for Audioeye, Inc. Investors
If you purchased or otherwise acquired shares of Audioeye, Inc., you may have legal claims under federal securities laws. You may contact Gilman Law LLP to discuss your rights to recovery of your losses or to obtain additional information.

About Our Investment Fraud Attorneys
The Securities Fraud Attorneys at Gilman Law have over 35 years of experience in securities litigation. Our Investment Fraud Attorneys focus on cases involving securities litigation, securities fraud, mergers and acquisitions, breach of fiduciary duty and other shareholder disputes.

For a free evaluation of your case or to obtain additional information, please complete the Investor Certification or CALL TOLL FREE (888) 252-0048.

Posted in General Legal News | Comments closed

ALTISOURCE RESIDENTIAL CORPORATION LAWSUIT (RESI)

Class Action Lawsuit Against Altisource Residential Corporation on Behalf of Altisource

Residential Corporation Investors

Altisource Residential Corporation Lawsuit Details
On March 27, 2015, a securities class action lawsuit was filed on behalf of purchasers of Altisource Residential Corporation (NASDAQ: RESI)) common stock. The complaint alleges violations of federal securities laws, including alleging the issuance of materially false and misleading representations to the market which had the effect of artificially inflating the market price of the Company stock beginning February 7, 2013 through January 23, 2015. The lawsuit alleges that Altisource Residential Corporation made materially false statements regarding the Company’s relationship with Ocwen Financial Corporation and the risks relating to its relationship with Ocwen.

Altisource Residential Corporation Lawsuit

Altisource Residential Corporation Lawsuit

Legal Help for Altisource Residential Corporation Investors
If you purchased or otherwise acquired shares of Altisource Residential Corporation, you may have legal claims under federal securities laws. You may contact Gilman Law LLP to discuss your rights to recovery of your losses or to obtain additional information.

About Our Investment Fraud Attorneys
The Securities Fraud Attorneys at Gilman Law have over 35 years of experience in securities litigation. Our Investment Fraud Attorneys focus on cases involving securities litigation, securities fraud, mergers and acquisitions, breach of fiduciary duty and other shareholder disputes.

For a free evaluation of your case or to obtain additional information, please complete the Investor Certification or CALL TOLL FREE (888) 252-0048.

Posted in Current Lawsuits & Investigations | Tagged , , , | Comments closed

AKORN, INC. LAWSUIT (AKRX)

Class Action Lawsuit Against Akorn, Inc. on Behalf of Akorn, Inc. Investors

Akorn, Inc. Lawsuit Details
On March 4, 2015, a securities class action lawsuit was filed on behalf of purchasers of Akorn, Inc. (NASDAQ: AKRX)) common stock. The complaint alleges violations of federal securities laws,including alleging the issuance of materially false and misleading representations to the market which had the effect of artificially inflating the market price of the Company stock beginning April 17, 2014 through March 2, 2015.  The complaint alleges that Akorn failed to disclose it was lagging in integrating recent acquisitions into its accounting systems.

Akorn, Inc. Lawsuit

Akorn, Inc. Lawsuit

Legal Help for Akorn, Inc. Investors
If you purchased or otherwise acquired shares of Akorn, Inc., you may have legal claims under federal securities laws. You may contact Gilman Law LLP to discuss your rights to recovery of your losses or to obtain additional information.

About Our Investment Fraud Attorneys
The Securities Fraud Attorneys at Gilman Law have over 35 years of experience in securities litigation. Our Investment Fraud Attorneys focus on cases involving securities litigation, securities fraud, mergers and acquisitions, breach of fiduciary duty and other shareholder disputes.

For a free evaluation of your case or to obtain additional information, please complete the Investor Certification or CALL TOLL FREE (888) 252-0048.

Posted in Current Lawsuits & Investigations | Tagged , , , | Comments closed

ACCELERATE DIAGNOSTICS, INC LAWSUIT: (AXDX)

Class Action Lawsuit Against Accelerate Diagnostics, Inc. on Behalf of Accelerate Diagnostics, Inc. Investors

Accelerate Diagnostics, Inc. Lawsuit Details
On March 19, 2015, a securities class action lawsuit was filed on behalf of purchasers of Accelerate Diagnostics, Inc. (NASDAQ: AXDX) common stock. Specifically, the complaint alleges violations of the federal securities laws, including alleging the issuance of material false and misleading representations to the market which had the effect of artificially inflating the market price of the Company stock beginning March 7, 2014 through February 17, 2015. The lawsuit alleges that the Company misrepresented the capability and description of its main product, the ID/AST system (formally known as the BACcel system).

Accelerate Diagnostics, Inc. Lawsuit Details Lawsuit

Accelerate Diagnostics, Inc. Lawsuit

Legal Help for Accelerate Diagnostics, Inc. Investors
If you purchased or otherwise acquired shares of Accelerate Diagnostics, Inc., you may have legal claims under federal securities laws. You may contact Gilman Law LLP to discuss your rights to recovery of your losses or to obtain additional information.

About Our Investment Fraud Attorneys
The Securities Fraud Attorneys at Gilman Law have over 35 years of experience in securities litigation. Our Investment Fraud Attorneys focus on cases involving securities litigation, securities fraud, mergers and acquisitions, breach of fiduciary duty and other shareholder disputes.

For a free evaluation of your case or to obtain additional information, please complete the Investor Certification or CALL TOLL FREE (888) 252-0048.

Posted in Current Lawsuits & Investigations | Comments closed

THE MEDICINES COMPANY INVESTIGATION

Gilman Law LLP is Investigating The Medicines Company on Behalf of Purchasers of The Medicines Company Stock

About the The Medicines Company
The Investment Fraud Attorneys of Gilman Law LLP announce they are investigating potential federal securities law claims on behalf of investors in The Medicines Company (NASDAQ:MDCO) common stock.

The Medicines Company Details of Investigation
On April 9, 2015, The Medicines Company announced that it expects net revenue in the range of $125 million to $130 million for the first quarter of 2015, which reflects a 29% to 26% decrease from the first quarter of 2014 due to lowering sales of Angiomax. The Company expects net revenue from sales of Angiomax to be in the range of $97 million to $105 million compared to $155.7 million in the first quarter of 2014. The Chairman and CEO of The Medicines Company, Clive Meanwell, stated that the declining sale of Angiomax “reflects our customers’ current uncertainty regarding the product’s patent exclusivity in the United States past June 2015” and that “[w]e appreciate our customers’ concerns about managing their pharmaceutical inventories.”

The Medicines Company

The Medicines Company Investigation

Legal Help for The Medicines Company Investors
If you purchased or otherwise acquired shares of The Medicines Company, you may have legal claims under federal securities laws. You may contact Gilman Law LLP to discuss your rights to recovery of your losses or to obtain additional information.

About Our Investment Fraud Attorneys
The Securities Fraud Attorneys at Gilman Law have over 35 years of experience in securities litigation. Our Investment Fraud Attorneys focus on cases involving securities litigation, securities fraud, mergers and acquisitions, breach of fiduciary duty and other shareholder disputes.

For a free evaluation of your case or to obtain additional information, please complete the Investor Certification or CALL TOLL FREE (888) 252-0048.

Posted in Current Lawsuits & Investigations | Comments closed

OHR PHARMACEUTICALS, INC. INVESTIGATION

Gilman Law LLP is Investigating OHR Pharmaceuticals, Inc. on Behalf of Purchasers of OHR Pharmaceuticals, Inc. Stock

About the OHR Pharmaceuticals, Inc.
The Investment Fraud Attorneys of Gilman Law LLP announce they are investigating potential federal securities law claims on behalf of investors in Ohr Pharmaceutical, Inc. (NASDAQ: OHRP) common stock.

OHR Pharmaceuticals, Inc. Details of Investigation
On March 27, 2015, Ohr Pharmaceutical announced the results of a mid-stage study of its lead drug, OHR-102. The study was designed to determine whether the drug could be used in tandem with the existing treatment, injectable eye drug Lucentis, to reduce the number of Lucentis injections patients required. But Ohr announced that there was no “meaningful” reduction in the number of injections required when OHR-102 was used, and that its study had thus failed its primary endpoint.

OHR Pharmaceuticals, Inc.

OHR Pharmaceuticals, Inc. Investigation

Legal Help for OHR Pharmaceuticals, Inc. Investors
If you purchased or otherwise acquired shares of OHR Pharmaceuticals, Inc., you may have legal claims under federal securities laws. You may contact Gilman Law LLP to discuss your rights to recovery of your losses or to obtain additional information.

About Our Investment Fraud Attorneys
The Securities Fraud Attorneys at Gilman Law have over 35 years of experience in securities litigation. Our Investment Fraud Attorneys focus on cases involving securities litigation, securities fraud, mergers and acquisitions, breach of fiduciary duty and other shareholder disputes.

For a free evaluation of your case or to obtain additional information, please complete the Investor Certification or CALL TOLL FREE (888) 252-0048.

Posted in General Legal News | Comments closed

POLYCOM, INC. INVESTIGATION

Gilman Law LLP is Investigating Polycom, Inc. on Behalf of Purchasers of Polycom, Inc. Stock

About the Polycom, Inc. Investigation
The Investment Fraud Attorneys of Gilman Law LLP announce they are investigating potential federal securities law claims on behalf of investors in Polycom, Inc. (NASDAQ: PLCM) common stock.

Polycom, Inc. Details of Investigation
The Securities and Exchange Commission (“SEC”) recently charged Polycom CEO Andrew Miller with using nearly $200,000 in corporate funds for personal perks that were not disclosed to investors, including travel to luxury resorts with his girlfriend.  Specifically, the SEC alleges that Miller engaged in a long-running scheme to surreptitiously use Polycom funds to pay for his personal expenses, including lavish meals, foreign and domestic travel, clothing, gifts and entertainment for himself, and his relatives and friends.  The SEC also alleges that from approximately 2010 until his resignation as CEO on July 19, 2013, Miller falsified, and caused others to falsify, business records in order to hide his scheme.  The SEC also alleges that Polycom repeatedly made misleading public statements to investors concerning such perquisites.

On July 23, 2013, Polycom announced that Miller had resigned and that the Company had found irregularities in Miller’s expense submissions, for which Miller had accepted responsibility.

Polycom Inc. Investigation

Polycom, Inc. Investigation

Legal Help for Polycom, Inc. Investors
If you purchased or otherwise acquired shares of Polycom, Inc., you may have legal claims under federal securities laws. You may contact Gilman Law LLP to discuss your rights to recovery of your losses or to obtain additional information.

About Our Investment Fraud Attorneys
The Securities Fraud Attorneys at Gilman Law have over 35 years of experience in securities litigation. Our Investment Fraud Attorneys focus on cases involving securities litigation, securities fraud, mergers and acquisitions, breach of fiduciary duty and other shareholder disputes.

For a free evaluation of your case or to obtain additional information, please complete the Investor Certification or CALL TOLL FREE (888) 252-0048.

Posted in Current Lawsuits & Investigations | Tagged , , , , | Comments closed

NEKTAR THERAPEUTICS INVESTIGATION

Gilman Law LLP is Investigating Nektar Therapeutics on Behalf of Purchasers of Nektar Therapeutics Stock

About the Nektar Therapeutics Investigation
The Investment Fraud Attorneys of Gilman Law LLP announce they are investigating potential federal securities law claims on behalf of investors in Nektar Therapeutics (NASDAQ: NKTR) common stock.

Nektar Therapeutics Details of Investigation
On March 17, 2015, Nektar reported that results from a Phase 3 BEACON study of its experimental breast cancer drug, NKTR-102, failed to achieve the primary endpoint of overall survival.  Further, the study failed to achieve statistical significance in the secondary endpoints of objective response rate (ORR) and progression-free survival (PFS).

Nektar Therapeutics Investigation

Nektar Therapeutics Investigation

Legal Help for Nektar Therapeutics Investors
If you purchased or otherwise acquired shares of Nektar Therapeutics, you may have legal claims under federal securities laws. You may contact Gilman Law LLP to discuss your rights to recovery of your losses or to obtain additional information.

About Our Investment Fraud Attorneys
The Securities Fraud Attorneys at Gilman Law have over 35 years of experience in securities litigation. Our Investment Fraud Attorneys focus on cases involving securities litigation, securities fraud, mergers and acquisitions, breach of fiduciary duty and other shareholder disputes.

For a free evaluation of your case or to obtain additional information, please complete the Investor Certification or CALL TOLL FREE (888) 252-0048.

Posted in General Legal News | Tagged , , , | Comments closed

SONUS NETWORKS LAWSUIT (SONS)

Class Action Lawsuit Against Sonus Networks on Behalf of Sonus Networks Investors

Sonus Networks Lawsuit Details
Gilman Law LLP has announced that a federal securities class action lawsuit was filed on behalf of purchasers of Sonus Networks, Inc. (NASDAQ: SONS) common stock. The complaint alleges violations of federal securities laws, including alleging the issuance of materially false and misleading representations to the market which had the effect of artificially inflating the market price of the Company stock beginning October 23, 2014 through March 24, 2015.

The lawsuit alleges that Sonus made false and/or misleading statements and/or failed to disclose that: (1) the Company would be unable to close certain orders in the first quarter of 2015; and (2) the Company was experiencing longer decision cycles from its customers.

Sonus Networks Lawsuit

Sonus Networks Lawsuit

Legal Help for Sonus Networks Investors
If you purchased or otherwise acquired shares of Sonus Networks, you may have legal claims under federal securities laws. You may contact Gilman Law LLP to discuss your rights to recovery of your losses or to obtain additional information.

About Our Investment Fraud Attorneys
The Securities Fraud Attorneys at Gilman Law have over 35 years of experience in securities litigation. Our Investment Fraud Attorneys focus on cases involving securities litigation, securities fraud, mergers and acquisitions, breach of fiduciary duty and other shareholder disputes.

For a free evaluation of your case or to obtain additional information, please complete the Investor Certification or CALL TOLL FREE (888) 252-0048.

Posted in Current Lawsuits & Investigations | Tagged , , , | Comments closed

YOUKU TUDOU LAWSUIT (YOKU)

Class Action Lawsuit Against Youku Tudou on Behalf of Youku Tudou Investors

Youku Tudou Lawsuit Details
Gilman Law LLP announced that a class action lawsuit has been filed on behalf of purchasers of the securities of Youku Tudou (NASDAQ: YOKU) between February 27, 2014 and March 19, 2015 under the federal securities laws.

Youku Tudou Lawsuit

Legal Help for Youku Tudou Investors
If you purchased or otherwise acquired shares of Youku Tudou, you may have legal claims under federal securities laws. You may contact Gilman Law LLP to discuss your rights to recovery of your losses or to obtain additional information.

About Our Investment Fraud Attorneys
The Securities Fraud Attorneys at Gilman Law have over 35 years of experience in securities litigation. Our Investment Fraud Attorneys focus on cases involving securities litigation, securities fraud, mergers and acquisitions, breach of fiduciary duty and other shareholder disputes.

For a free evaluation of your case or to obtain additional information, please complete the Investor Certification or CALL TOLL FREE (888) 252-0048.

Posted in General Legal News | Tagged , , , | Comments closed

Awards & Recognition

The Securities and Investment Fraud Attorneys at Gilman Law LLP have been recognized by numerous leading legal publications:

Investment Losses Law Firm